Caris Life Sciences, Inc.
CAI
$16.96
$0.825.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 78.78% | 125.44% | 113.38% | 81.31% | 49.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 78.78% | 125.44% | 113.38% | 81.31% | 49.88% |
| Cost of Revenue | 17.19% | 21.77% | 21.18% | 8.35% | 17.02% |
| Gross Profit | 147.71% | 207.93% | 232.13% | 202.72% | 118.51% |
| SG&A Expenses | 13.92% | 23.44% | 20.14% | 33.65% | 9.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.91% | 22.47% | 13.37% | 19.35% | 3.45% |
| Operating Income | 109.11% | 338.65% | 153.65% | 73.16% | 37.16% |
| Income Before Tax | 99.37% | 321.82% | 135.92% | -8.47% | 7.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 99.50% | 321.82% | 135.92% | -8.47% | 7.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 99.50% | 321.82% | 135.92% | -8.47% | 7.61% |
| EBIT | 109.11% | 338.65% | 153.65% | 73.16% | 37.16% |
| EBITDA | 120.33% | 431.32% | 174.56% | 79.10% | 31.69% |
| EPS Basic | 99.95% | 116.72% | 103.33% | -213.88% | 6.12% |
| Normalized Basic EPS | 99.92% | 128.71% | 104.54% | 55.66% | 8.41% |
| EPS Diluted | 99.95% | 115.98% | 103.09% | -213.88% | 6.12% |
| Normalized Diluted EPS | 99.92% | 127.35% | 104.31% | 55.66% | 8.41% |
| Average Basic Shares Outstanding | 693.20% | 691.44% | 691.44% | 83.54% | 0.88% |
| Average Diluted Shares Outstanding | 693.20% | 730.35% | 733.84% | 83.54% | 0.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |